Imatinib Completed Phase 2 Trials for Imatinib Mesylate / Sclerotic Graft Versus Host Disease Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00702689Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease